Navigation Links
Molecule plays early role in nonsmoking lung cancer
Date:7/27/2009

COLUMBUS, Ohio The cause of lung cancer in never-smokers is poorly understood, but a study led by investigators at the Ohio State University Comprehensive Cancer Center and at the National Cancer Institute has identified a molecule believed to play an early and important role in its development.

The findings, published online recently in the Proceedings of the National Academy of Sciences, may lead to improved therapy for lung cancer in both never-smokers and smokers, including those with tumors resistant to targeted drugs such as gefitinib.

The study examined lung tumors from people who had never smoked and found high levels of a molecule called miR-21. The levels were even higher in tumors that had mutations in a gene called EGFR, a common feature of lung cancer in never-smokers.

"Several important lung cancer drugs target EGFR mutations, but these agents are ineffective in about 30 percent of cases in which the mutation is present," says co-principal investigator Dr. Carlo M. Croce, professor of molecular virology, immunology and medical genetics at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. "Our study suggests that developing agents to inhibit miR-21 might improve these anti-EGFR therapies."

About 15 percent of the 219,000 lung cancer cases expected this year in the United States 32,850 people will occur in individuals who have never smoked.

Croce and his colleagues began their study by comparing 28 cases of lung tumor tissue and nearby healthy lung tissue from never-smokers for changes in microRNA, molecules that help cells regulate the kind and amount of proteins they make.

The cancer cells showed abnormally elevated levels of five microRNAs, with miR-21 increased two and a third times, the highest of all. An earlier study of smoking-related lung cancer by the same investigators also showed elevated levels of that molecule.

Furthermore, the molecule was equally high in early stage tumors and late stage tumors, suggesting that this change happens early in lung cancer development, says Croce, who also directs Ohio State's Human Cancer Genetics program.

Using lung cancer cell lines, the investigators learned that EGFR regulates miR-21. For example, altering EGFR levels caused corresponding changes in miR-21.

Last, the investigators took cells that had a mutated EGFR gene and treated them with an anti-EGFR agent (the agent was related to gefitinib and erlotinib, targeted drugs used to treat lung cancers with EGFR mutations). As expected, many of the cells died. But when they blocked both EGFR and miR-21, the proportion of cells killed rose still more.

Overall, Croce says, "Our study suggests that the combined use of an EGFR inhibitor and a miR-21 inhibitor might improve therapy for many cases of lung cancer, and rescue lung cancer cases that have acquired resistance to several targeted drugs."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Molecule Helps Leukemia Cells Hide From Immune System
2. Small Molecule Might Play Big Part in Lung Cancer
3. New role discovered for molecule important in development of the pancreas
4. Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway
5. Ready for relapse: Molecule helps breast cancer cells to survive in the bone marrow
6. LSUHSC research identifies enzyme that makes survival molecule for key vision cells
7. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
8. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
9. Molecule in Skin May Link Eczema and Asthma
10. Molecule prompts damaged heart cells to repair themselves after a heart attack
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Tribble Insurance Agency, a family owned and ... is inaugurating a charity event to honor Chad Phillip Dermyer, a local police trooper ... Chad Phillip Dermyer and his fellow officers were conducting routine stops of suspects when ...
(Date:1/19/2017)... Madison, Mississippi (PRWEB) , ... January 19, 2017 , ... ... its Siena Center. , Siena Center is a skilled nursing facility on the grounds ... private and semiprivate rooms. It recently was voted the best nursing home in Mississippi ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Spring Create Real Impact contest from Impact Teen Drivers and California Casualty. Entries ... . , Educational grants totaling $15,000 will be awarded for the best ...
(Date:1/19/2017)... ... ... The CHP suggests that California drivers can avoid hydroplaning as well as ... the space between themselves and other vehicles, according to a January 3 article ... notes that, rain or shine, drivers should always incorporate safe driving practices in their ...
(Date:1/19/2017)... ... ... Connecticut Dermatology Group (CDG) is proud and excited to welcome back to ... Kim brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest ... Dr. Kim to the CDG team” said President and Managing Partner Dr. Steven A. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... and TomoTherapy® Systems continue to set the bar for ... highest composite overall user satisfaction rating among radiation treatment ... 2016 MD Buyline Market Intelligence Briefing™. The most recent ... composite ratings among industry peers for 11 of the ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange ... excited to announce that the first five replication ...  (RP:CB) have been published in eLife today. Despite ... represents the first practical evaluation of reproducibility rates ... reproducible studies. Unlike other assessments of reproducibility, the ...
Breaking Medicine Technology: